Amlodipine/atorvastatin/perindopril - IRIS

Drug Profile

Amlodipine/atorvastatin/perindopril - IRIS

Alternative Names: Lipertance; S-05153; Statriam; Triveram

Latest Information Update: 24 Oct 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator IRIS
  • Developer IRIS; Servier
  • Class Antihyperlipidaemics; Antihypertensives; Small molecules
  • Mechanism of Action ACE inhibitors; Calcium channel antagonists; HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Dyslipidaemias; Hypertension

Most Recent Events

  • 08 Sep 2016 Iris completes a phase-III clinical trial for Hypertension and Dyslipidaemias in Bulgaria (PO) (EudraCT2014-005378-12)
  • 05 Jan 2016 Phase-III clinical trials in Dyslipidaemias in Bulgaria (PO) (EudraCT2014-005378-12)
  • 05 Jan 2016 Phase-III clinical trials in Hypertension in Bulgaria (PO) (EudraCT2014-005378-12)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top